Search Results
270 Results for 'Therapeutics & Vaccines'
PAGE 5 OF 11
Technology
Generation of Wild Type and Mutant Ebola Virus from Cloned cDNA
Ebola Virus Disease (EVD) is a severe and highly fatal hemorrhagic fever that affects humans and other mammals. It is caused by the Ebola virus, a single-stranded RNA virus that encodes seven structur...
Learn More
Learn More
Yoshihiro Kawaoka, Gabriele Neumann, Luke Jasenosky | P01214US02
Technology
CHO Cell Line Expressing HERG-1 Potassium Channels
HERG-1 (human ether-a-go-go-related gene) potassium channels mediate repolarization of cardiac action potentials. Loss of function mutations in hERG-1 can result in long QT syndrome, an inherited diso...
Learn More
Learn More
Gail Robertson, Barry Ganetzky, Jeffrey Warmke, Matthew Trudeau, Samuel Breit, Terence Campbell, Bruce Walker, Stella Valenzuela | P00082US
Technology
Methods to Screen Antifungal Compounds and Treat Fungal Diseases by Inhibiting Spore Germination
Every year worldwide, millions of people experience morbidity and mortality as a consequence of severe fungal disease. In the United States, mortality from invasive fungal disease is approximately 50 ...
Learn More
Learn More
Christina Hull, Mingwei Huang, Sébastien Ortiz | P180117US02
Technology
LPS Priming of Stromal Cells to Generate LPS-specific Exosome Educated Macrophages
Currently there are no cell therapies approved for use against acute radiation injury (ARS). Severe ARS can cause death and the only cell treatment is allogenic bone marrow transplantation (BMT). Unfo...
Learn More
Learn More
Peiman Hematti, John Kink, Christian Capitini | P170215US02
Technology
A ‘Humanized’ MDCK Cell Line For the Efficient Isolation and Amplification of Seasonal Human Influenza Viruses
Most influenza vaccines are produced in embryonated chicken eggs, but increasingly influenza vaccines are produced in other systems. MDCK (Madin-Darby Canine Kidney) cells are one of two mammalian cel...
Learn More
Learn More
Yoshihiro Kawaoka, Kosuke Takada, Masaki Imai | P180301US04
Technology
Ph-Responsive Polymer–Antibiotic Conjugate For Enhanced Antimicrobial Efficacy
Provided herein are polymer-drug conjugates with enhanced antibacterial efficacy. These conjugates include a polymer comprising a plurality of masked cationic functional groups and an antibiotic drug ...
Learn More
Learn More
Shaoqin Gong, Mingzhou Ye | P200087US02
Technology
COVID-19 Vaccine
Provided herein are antigenic peptides comprising the SARS-CoV-2 spike protein receptor binding domain (CRBD) polypeptide or portions thereof, linked to a non-catalytic, nontoxic tetanus toxin varia...
Learn More
Learn More
Joseph Barbieri, Eric Johnson, Sabine Pellett, William Tepp, Amanda Przedpelski | P200268US03
Technology
RSV Virus-Like Particles And Methods Of Use Thereof
The present disclosure relates to vims-like particles and vaccine compositions for inducing immunity and preventing respiratory syncytial vims (RSV) infection. Specifically, the disclosure provides vi...
Learn More
Learn More
Elizabeth Wright, Larry Anderson, Binh Ha | P200021US02
Technology
Influenza M2 Protein Mutant Viruses As Influenza Live Attenuated Vaccines
A method to prepare recombinant influenza viruses comprising a mutant M2 protein which has a deletion of two or more residues in the cytoplasmic tail and is attenuated in vivo, is provided, as well th...
Learn More
Learn More
Yoshihiro Kawaoka, Tokiko Watanabe | P07509US
Technology
Once-A-Week Administration Of 25-Hydroxy Vitamin D3 To Sustain Elevated Steady-State Pharmacokinetic Blood Concentration
An oral dosage form comprising a single dose of 25-hydroxy-vitamin D3 sufficient to elevate the serum level in a human to a concentration in the range of 30 ng/ml to 200 ng/ml for at least 7 days and ...
Learn More
Learn More
Hector DeLuca, Lori Plum, Margaret Clagett-Dame | P08138US02
Technology
Reversible Natural Product Glycosyltransferase-catalyzed Reactions, Compounds And Related Methods
The present invention relates to methods of use of glycosyltransferases and related compounds. The invention exploits the reversibility of glycosyltransferases to generate new sugars, unnatural biomol...
Learn More
Learn More
Jon Thorson, Byron Griffith, Changsheng Zhang | P06427US
Technology
Methods For Preventing And Attenuating Hyperphosphatemia
It is disclosed here a method for reducing phosphate absorption in a human or non-human animal subject wherein the subject consumes a diet containing phytic acid or phytate and either has or is at ris...
Learn More
Learn More
Mark Cook, Keith Crawford, Erica Hellestad, Martin Petkovich, Christian Helvig | P06481US
Technology
Compositions And Methods For Treating Hyperphosphatemia In Humans
A method for reducing phosphate absorption in a human or non-human animal subject at risk of developing or having developed hyperphosphatemia is disclosed. The method includes the step of administerin...
Learn More
Learn More
Mark Cook, Keith Crawford, Erica Hellestad, Christian Helvig, Martin Petkovich | P07020US
Technology
2-methylene-1alpha,25-dihydroxy-18,19,21-trinorvitamin D3 And Uses Thereof
This invention relates to vitamin D compounds, and more particularly to 2-methylene-1 α,25-dihydroxy-18,19,21-trinorvitamin D3 (DJ-55) and to pharmaceutical formulations that include this compound. T...
Learn More
Learn More
Hector DeLuca, Rafal Barycki, Lori Plum, Margaret Clagett-Dame | P06327US
Technology
2-methylene-19-nor-(23s)-25-dehydro-1alpha-hydroxyvitamin D3-26,23-lactone And 2-methylene-19-nor-(2
The invention provides 2-methylene-19-nor-(23R)-25-dehydro-1α-hydroxyvitamin D3-26,23-lactone (“GC-3”), 2-methylene-19-nor-(23S)-25-dehydro-1α-hydroxyvitamin D3-26,23-lactone (“HLV”), and re...
Learn More
Learn More
Hector DeLuca, Margaret Clagett-Dame, Lori Plum, Pawel Grzywacz, Grazia Chiellini | P05291US
Technology
19,26,27-trinor-1alpha,25-dihydroxyvitamin D3 Compounds
This invention relates to vitamin D compounds, and more particularly to 19,26,27-trinor-1α,25-dihydroxyvitamin D3 compounds such as 2α-methyl-19,26,27-trinor-(20S)-1α,25-dihydroxyvitamin D3 (“P...
Learn More
Learn More
Hector DeLuca, Lori Plum, Pawel Grzywacz, Margaret Clagett-Dame | P05370US
Technology
17,20(z)-dehydro Vitamin D Analogs And Their Uses
This invention discloses 17,20(Z)-dehydro vitamin D analogs, and specifically 17(Z)-1α,25-dihydroxy-17(20)-dehydro-2-methylene-19-nor-vitamin D3 and pharmaceutical uses therefor. This compound exhibi...
Learn More
Learn More
Hector DeLuca, Margaret Clagett-Dame, Lori Plum, Bulli Padmaja Tadi | P06097US
Technology
17,20(e)-dehydro Vitamin D Analogs And Their Uses
This invention discloses 17,20(E)-dehydro vitamin D analogs, and specifically 17(E)-1α,25-dihydroxy-17(20)-dehydro-2-methylene-19-nor-vitamin D3 and pharmaceutical uses therefor. This compound exhibi...
Learn More
Learn More
Hector DeLuca, Margaret Clagett-Dame, Lori Plum, Bulli Padmaja Tadi | P06117US
Technology
Metabolic-based Methods For Modulating Gene Expression
This invention provides methods for modulating cellular gene expression for genes operably linked to an NRSE element that is recognized by an NRSF transcriptional repressor, by changing the concentrat...
Learn More
Learn More
Thomas Sutula, Avtar Roopra, Barry Schoenike | P05137US
Technology
2alpha-methyl-19-nor-(20s)-1alpha-hydroxy-bishomopregnacalciferol And Its Uses
This invention discloses 2α-methyl-19-nor-(20S)-vitamin D analogs, and specifically 2α-methyl-19-nor-(20S)-1α-hydroxy-bishomopregnacalciferol and pharmaceutical uses therefor. This compound exhibit...
Learn More
Learn More
Hector DeLuca, Lori Plum, Rafal Sicinski, Margaret Clagett-Dame | P05163US
Technology
Treatment Of Sinusitis Related Chronic Facial Pain And Headache With Botulinum Toxin Injections
The present invention provides methods for treating sinus-evoked headaches using botulinum toxin injected or applied in multiple subcutaneous locations over divisions of the trigeminal nerve in soft t...
Learn More
Learn More
Gary Borodic, Martin Acquadro | P05053US
Technology
2-methylene-19,26,27-trinor-(20s)-1alpha-hydroxyvitamin D3 And Its Uses
This invention discloses 2-methylene-19,26,27-trinor-(20S)-vitamin D analogs, and specifically 2-methylene-19,26,27-trinor-(20S)-1α-hydroxyvitamin D3 and pharmaceutical uses therefor. This compound e...
Learn More
Learn More
Hector DeLuca, Pawel Grzywacz, Lori Plum, Margaret Clagett-Dame | P05125US
Technology
2alpha-methyl And 2beta- Methyl Analogs Of 19,26,27-trinor-(20s)-1alpha-hydroxyvitamin D3 And Their
This invention discloses 2α-methyl and 2β-methyl analogs of 19,26,27-trinor-(20S)-1α-hydroxyvitamin D3 and pharmaceutical uses therefor. These compounds exhibit pronounced activity in arresting the...
Learn More
Learn More
Hector DeLuca, Pawel Grzywacz, Lori Plum, Margaret Clagett-Dame | P05127US
Technology
1-Alpha, 25-Dihydroxy-24,24-Difluoro-19-Nor-Vitamin D3 Analogs And Their Pharmaceutical Uses
Disclosed are 1α,25-dihydroxy-24,24-difluoro-2-methylene-19-nor-vitamin D analogs and their pharmaceutical uses. These new vitamin D analogs are 19-nor-vitamin D analogs having two fluorine atom subs...
Learn More
Learn More
Hector DeLuca, Lori Plum, Agnieszka Flores, Hazel Holden, James Thoden | P150305US02
Technology
Influenza Virus Replication For Vaccine Development
The invention provides a composition useful to prepare high titer influenza viruses, e.g., in the absence of helper virus, which includes internal genes from an influenza virus vaccine strain or isola...
Learn More
Learn More
Yoshihiro Kawaoka, Gabriele Neumann, Jihui Ping | P150360US02